Plain-English translation of NCT05926011 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing RGn600, a light therapy device designed to help people with mild-to-moderate Alzheimer's disease. Half of the participants will receive the active device, while the other half will receive an inactive (sham) version, so researchers can fairly compare how well this treatment works. Over six months, you'll have treatment sessions, and then researchers will follow you for an additional six months to see if the therapy helps with memory, daily activities, and quality of life.
Current treatments for Alzheimer's disease only help manage symptoms for some people, and researchers are looking for new approaches to slow memory loss and help people stay independent longer. This trial is testing whether light therapy might be a safe and effective additional option.
You likely qualify if…
You likely don't qualify if…
You will come to a research clinic for treatment sessions over six months: 5 sessions per week for the first 8 weeks, then 3 sessions per week for 8 weeks, and finally 2 sessions per week for the last 10 weeks. Each session lasts about 20 minutes. You'll also have four main assessment visits (at the start, 8 weeks, 26 weeks, and 52 weeks) where doctors will test your memory, ask about your daily activities and quality of life, and run safety checks including blood tests. Your caregiver will be involved in several parts of the study to help support you.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
France